Phynova (AIM: PYN), a botanical drug company based in Oxford, UK, says it will now re-focus its efforts on China, with an emphasis on the China market, China drugs and perhaps some China acquisitions. Phynova has always had a China connection, including a 45% share in Botanic Century Beijing Ltd, a drug development company. Until now, Phynova has been using TCM preparations as a basis for developing drugs that would address unmet needs and pass clinical trials in the west. More details...